DOCSLIB.ORG

S. Aureus and MDR CNS DAP and DAP MSSA and MRSA Proteins Recently Completed a Phase 2 Clinical Trial for Treatment of Staphylococcus- Associated ABSSSI

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
S. Aureus and MDR CNS DAP and DAP MSSA and MRSA Proteins Recently Completed a Phase 2 Clinical Trial for Treatment of Staphylococcus- Associated ABSSSI POSTER NUMBER Activity of Brilacidin (PMX-30063) Against E-1474 Drug Resistant Staphylococci 170 N. Radnor Chester Rd., Suite 300 52nd Interscience Conference on Radnor, PA 19087-5221 USA Antimicrobial and Chemotherapy (ICAAC) 1 1 2 2 3 3 4,5 4,5 R. Scott , B. Korczak , D. Jorgensen , S. Hawser , M. Hackel , S. Bouchillon , Y. Xiong , A. Bayer www.polymedix.com September 9-12 , 2012 Tel:(484) 598-2400 San Francisco, CA, USA 1Polymedix, Radnor, PA; 2IHMA Europe Sàrl, Epalinges, CH; 3IHMA, Inc., Schaumburg, IL, USA; 4LA Biomed. Res. Inst., Torrance, CA; 5Geffen Sch. of Med. at UCLA, Los Angeles, CA ABSTRACT RESULTS: RESULTS: CLINICAL ISOLATE SCREEN Brilacidin vs. ISOGENIC STRAIN PAIRS OF S R Background: Brilacidin (PMX-30063), a small nonpeptidic mimic of host defense MDR S. aureus and MDR CNS DAP and DAP MSSA and MRSA proteins recently completed a Phase 2 clinical trial for treatment of Staphylococcus- associated ABSSSI. Brilacidin is rapidly bactericidal against Gram-positive and Gram- negative pathogens. In the current studies, brilacidin was assessed against multi-drug resistant (MDR) S. aureus and coagulase-negative staphylococci (CNS) and six Table 1: Comparison of brilacidin activity vs. MDR S. aureus (n = 103) Table 4: Susceptibility (MIC and MBC) of the isogenic strain pairs vs. brilacidin S R Isogenic Strain Pairs isogenic strain pairs of daptomycin-sensitive (DAP ) and -resistant (DAP ) MSSA and S R [DAP I DAP ] MRSA. S R S R S R S R S R S R DAP I DAP DAP I DAP DAP I DAP DAP I DAP DAP I DAP DAP I DAP Clav Brilacidin and comparators were tested against 206 MDR staphylococci (103 / Methods: 214 215 11/11 2145 616 701 211 212 282 283 300 755 MDR S. aureus, 103 MDR CoNS). All single patient isolates were from 2010-2011 with Cefoxitin Ceftriaxone Daptomycin Levofloxacin Linezolid Meropenem Minocycline Tigecycline Vancomycin Brilacidin Amox MIC/MBC the exception of 19 isolates collected by the Network on Antibiotic Resistance in 1/1 1/1 1/1 1/1 1/1 1/1 1/1 2/2 1/1 2/2 1/1 1/1 1 >8 >4 >32 1 >4 2 8 0.06 0.12 1 (ug/ml) Staphylococcus aureus (NARSA) which were comprised of 10 vancomycin-resistant, 7 MIC50 2 >8 >4 >32 1 >4 4 >8 0.25 0.25 4 vancomycin-intermediate and 2 linezolid resistant isolates. MICs were determined by MIC90 broth microdilution according to CLSI guidelines. Time-kill studies were done under Mode 1 >8 >4 >32 1 >4 2 >8 0.06 0.12 1 CLSI conditions using polypropylene plasticware. Mean* 1.183 7.429 >4 31.572 0.880 3.313 2.139 4.512 0.088 0.110 1.136 Figure 1: Killing kinetics of brilacidin at 2x, 5x and 10x the MIC Range 1 - 2 2 - >8 4 ->4 16 ->32 0.5 ->2 0.25 ->4 1 - >8 0.03 ->8 ≤0.03 - 4 0.03 – 0.5 0.5 ->8 Results: MIC90 values for MDR staphylococci are shown in the Table below. Brilacidin S R *Geometric Mean; All values expressed as µg/ml; All clinical isolates were collected from 2010 – 2011. Ayala Strain 214 (DAP-S) vs 215 (DAP-R) Strain 11/11 (DAP-S) vs REF2145 (DAP-R) MICs for the DAP and DAP isogenic MRSA strain pairs were equivalent and killing 10.00 10.00 kinetics were rapid at 2x MICs and nearly identical over a 24 hour test period. 9.00 9.00 8.00 214 8.00 11/11 11/11(2X) 7.00 214(2X) 7.00 MIC90 (µg/ml) 214(5X) 11/11(5X) 6.00 Table 2: Comparison of brilacidin activity vs. MDR CoNS (n = 103) 214(10X) 6.00 11/11(10X) 5.00 5.00 2145 CFU/ml Antibiotic MDR S. aureus MDR CoNS NARSA 215 CFU/ml 10 10 2145(2X) 215(2X) 4.00 4.00 215(5X) 2145(5X) log Brilacidin 2 1 2 Log 3.00 3.00 215(10X) 2145(10X) Ceftriaxone >32 >32 >32 2.00 2.00 Clav / 1.00 1.00 Daptomycin 1 1 2 0 2 4 6 8 10 12 14 16 18 20 22 24 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (h) Time (h) Cefoxitin Ceftriaxone Daptomycin Levofloxacin Linezolid Meropenem Minocycline Tigecycline Vancomycin Levofloxacin >4 >4 >4 Brilacidin Amox Linezolid 4 2 >8 MIC50 1 8 >4 >32 1 >4 1 8 0.25 0.25 2 Strain 616 (DAP-S) vs 701 (DAP-R) Strain 211 (DAP-S) vs 212 (DAP-R) Meropenem >8 >8 >8 1 >8 >4 >32 1 >4 2 >8 0.5 0.5 2 10.00 MIC90 10.00 Minocycline 0.25 0.5 4 Mode 1 >8 >4 >32 1 >4 1 >8 0.06 0.25 2 9.00 9.00 616 8.00 8.00 211 616(2X) 211(2X) Tigecycline 0.25 0.5 0.25 Mean* 0.886 3.665 3.868 24.947 0.790 3.334 1.354 4.045 0.171 0.225 1.508 7.00 7.00 616(5X) 211(5X) 6.00 616(10X) Vancomycin 4 2 >8 Range 0.5 - 2 0.25 - >8 2 ->4 2 ->32 0.25 - 2 0.12 ->4 0.5 - 4 0.03 ->8 ≤0.03 - 4 0.06 – 2 0.5 -4 6.00 211(10X) CFU/ml 701 CFU/ml 5.00 5.00 212 10 701(2X) 10 *Geometric Mean; All values expressed as µg/ml; All clinical isolates were collected from 2010 – 2011; CoNS: 4.00 4.00 212(2X) : Brilacidin exhibited good activity against all MDR S. aureus, MDR CNS 701(5X) Conclusions Log Log 212(5X) coagulase-negative S. aureus 3.00 701(10X) 3.00 212(10X) and 19 NARSA isolates with an MIC range of 0.5 – 2 for the 225 isolates and MIC90 of 1 2.00 2.00 – 2 µg/ml. Excellent bactericidal activity of brilacidin was demonstrated against 6 1.00 1.00 S R 0 2 4 6 8 10 12 14 16 18 20 22 24 0 2 4 6 8 10 12 14 16 18 20 22 24 isogenic strain pairs of DAP and DAP MSSA and MRSA. These results combined with Time (h) Time (h) a previous screen of 131 MRSA isolates show that brilacidin is highly active in vitro Table 3: Comparison of brilacidin activity against sub-group isolates against MDR staphylococci (e.g. resistant to cephalosporins, daptomycin, levofloxacin, with specific resistance phenotypes (n = 19) Strain 282 (DAP-S) vs 283 (DAP-R) Strain 300 (DAP-R) vs 755 (DAP-S) meropenem and vancomycin). 10.00 10.00 Phenotype 9.00 9.00 282 Clav 8.00 8.00 300 (NARSA / 282(2X) 300(2X) 7.00 7.00 isolates) 282(5X) 300(5X) 6.00 282(10X) 6.00 300(10X) CFU/ml CFU/ml Cefoxitin Ceftriaxone Daptomycin Levofloxacin Linezolid Meropenem Minocycline Tigecycline Vancomycin Brilacidin Amox 5.00 283 5.00 755 10 INTRODUCTION 10 755(2X) 1 >8 >4 >32 2 >4 1 >8 0.06 0.12 2 4.00 283(2X) 4.00 VISA Log Log 283(5X) 755(5X) 3.00 3.00 283(10X) 755(10X) VISA 1 8 >4 >32 2 >4 1 8 1 0.12 2 2.00 2.00 R 1.00 1.00 Host defense proteins (HDPs) are an essential component of the innate immune VISA/Dap 1 8 >4 >32 >2 >4 2 8 ≤0.03 0.06 4 0 2 4 6 8 10 12 14 16 18 20 22 24 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (h) Time (h) system and display broad-spectrum action against bacteria, yeast, and fungus by VISA 1 >8 >4 >32 2 >4 2 >8 0.06 0.12 4 specifically disrupting their membranes rather than binding to specific molecular VISA 1 >8 >4 >32 2 >4 2 >8 0.12 0.25 4 Methods. MIC and time kill studies were done under CLSI conditions using polypropylene targets. Importantly, this mechanism is associated with a lower risk for the VISA 1 >8 >4 >32 2 >4 1 >8 ≤0.03 0.06 2 plasticware. All strain pairs are MRSA except 616/701 and 300/755 which are MSSA. development of resistance. It appears that HDPs are ideal therapeutic agents to R LZD 2 >8 >4 >32 1 >4 >8 >8 4 0.25 1 DAPS: daptomycin susceptible; DAPR: daptomycin resistant. treat infections. However, significant problems with stability, tissue penetration and LZDR 2 >8 >4 >32 1 >4 >8 >8 4 0.12 1 toxicity have hampered their clinical progress. PolyMedix has developed a series of R LZD 2 >8 >4 >32 0.5 >4 8 8 0.12 0.12 1 Results. small nonpeptidic mimics of the HDPs which have robust activity against bacteria VRSA 2 >8 >4 >32 1 >4 2 >8 0.5 0.25 >8 Table 4. Brilacidin was bactericidal vs. all strains of S. aureus. The MICs and MBCs for and markedly lower toxicity. The approach is to capture the structural and biological VRSA 1 >8 >4 >32 1 >4 2 >8 0.06 0.06 >8 brilacidin versus the DAPS and DAPR MSSA and MRSA isogenic strain pairs were within 1 properties of the HDPs on a fully synthetic, nonpeptidic framework that would be less VRSA 1 >8 >4 >32 0.5 >4 2 >8 2 0.12 >8 doubling dilution of each other, indicating that mechanisms associated with daptomycin expensive to produce, have better tissue distribution, and be much easier to fine- VRSA 2 >8 >4 >32 0.5 >4 2 >8 2 0.06 >8 resistance had little influence on susceptibility to brilacidin.
Load more

Recommended publications
  • Brilacidin First-In-Class Defensin-Mimetic Drug Candidate
    Brilacidin First-in-Class Defensin-Mimetic Drug Candidate Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment April 20, 2020 Page # I. Brilacidin: Background Information 2 II. Brilacidin: Two Primary Mechanisms of Action 3 Membrane Disruption 4 Immunomodulatory 7 III. Brilacidin: Several Complementary Ways of Targeting COVID-19 10 Antiviral (anti-SARS-CoV-2 activity) 11 Immuno/Anti-Inflammatory 13 Antimicrobial 16 IV. Brilacidin: COVID-19 Clinical Development Pathways 18 Drug 18 Vaccine 20 Next Steps 24 V. Brilacidin: Phase 2 Clinical Trial Data in Other Indications 25 VI. AMPs/Defensins (Mimetics): Antiviral Properties 30 VII. AMPs/Defensins (Mimetics): Anti-Coronavirus Potential 33 VIII. The Broader Context: Characteristics of the COVID-19 Pandemic 36 Innovation Pharmaceuticals 301 Edgewater Place, Ste 100 Wakefield, MA 01880 978.921.4125 [email protected] Innovation Pharmaceuticals: Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment (April 20, 2020) Page 1 of 45 I. Brilacidin: Background Information Brilacidin (PMX-30063) is Innovation Pharmaceutical’s lead Host Defense Protein (HDP)/Defensin-Mimetic drug candidate targeting SARS-CoV-2, the virus responsible for COVID-19. Laboratory testing conducted at a U.S.-based Regional Biocontainment Laboratory (RBL) supports Brilacidin’s antiviral activity in directly inhibiting SARS-CoV-2 in cell-based assays. Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1, TNF- and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients.
    [Show full text]
  • Current Topics in Medicinal Chemistry, 2017, 17, 576-589
    576 Send Orders for Reprints to [email protected] Current Topics in Medicinal Chemistry, 2017, 17, 576-589 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Impact Factor: Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic 2.9 The international journal for in-depth reviews on Applications Current Topics in Medicinal Chemistry BENTHAM SCIENCE Richard W. Scott*,1 and Gregory N. Tew2 1Fox Chase Chemical Diversity Center, Pennsylvania Biotechnology Center, Doylestown, PA, USA; 2Polymer Science and Engineering, Veterinary and Animal Science, Cell and Molecular Biology, University of Massachusetts, Amherst MA, USA Abstract: New infection treatments are urgently needed to combat the rising threat of multi-drug re- sistant bacteria. Despite early clinical set-backs attention has re-focused on host defense proteins (HDPs), as potential sources for new and effective antimicrobial treatments. HDPs appear to act at multiple targets and their repertoire includes disruptive membrane and intracellular activities against numerous types of pathogens as well as immune modulatory functions in the host. Importantly, these novel activities are associated with a low potential for emergence of resistance and little cross- resistance with other antimicrobial agents. Based on these properties, HDPs appear to be ideal candi- A R T I C L E H I S T O R Y dates for new antibiotics; however, their development has been plagued by the many therapeutic limi- tations associated with natural peptidic agents. This review focuses on HDP mimetic approaches Received: May 22, 2015 Revised: October 29, 2015 aimed to improve metabolic stability, pharmacokinetics, safety and manufacturing processes. Early ef- Accepted: November 30, 2015 forts with β-peptide or peptoid analogs focused on recreating stable facially amphiphilic structures but DOI: 10.2174/15680266166661607 demonstrated that antimicrobial activity was modulated by more, complex structural properties.
    [Show full text]
  • Advances in Antibiotic Therapy in the Critically Ill Jean-Louis Vincent1*, Matteo Bassetti2, Bruno François3, George Karam4, Jean Chastre5, Antoni Torres6, Jason A
    Vincent et al. Critical Care (2016) 20:133 DOI 10.1186/s13054-016-1285-6 REVIEW Open Access Advances in antibiotic therapy in the critically ill Jean-Louis Vincent1*, Matteo Bassetti2, Bruno François3, George Karam4, Jean Chastre5, Antoni Torres6, Jason A. Roberts7, Fabio S. Taccone1, Jordi Rello8, Thierry Calandra9, Daniel De Backer10, Tobias Welte11 and Massimo Antonelli12 In this review, we briefly highlight the importance of Abstract early infection diagnosis before discussing some of the Infections occur frequently in critically ill patients and key issues related to antibiotic management, including their management can be challenging for various problems associated with timing, duration, and dosing. reasons, including delayed diagnosis, difficulties We also briefly consider ventilator-associated pneumonia identifying causative microorganisms, and the high (VAP), the use of inhaled antibiotics, and new antibiotic prevalence of antibiotic-resistant strains. In this and adjunct strategies for the future. We focus on bacter- review, we briefly discuss the importance of early ial infections and issues associated with multi-drug resist- infection diagnosis, before considering in more detail ance will not be covered. some of the key issues related to antibiotic management in these patients, including controversies surrounding use of combination or monotherapy, duration of therapy, Diagnosis and de-escalation. Antibiotic pharmacodynamics and The diagnosis of infection in critically ill patients and pharmacokinetics, notably volumes of distribution and identification of causative microorganisms and their anti- clearance, can be altered by critical illness and can biotic susceptibilities can be a challenge and yet early, influence dosing regimens. Dosing decisions in different appropriate antibiotic therapy is associated with improved subgroups of patients, e.g., the obese, are also covered.
    [Show full text]
  • Antibiotics Currently in Clinical Development
    A data table from Feb 2014 Antibiotics Currently in Clinical Development As of February 2014, there are at least 45 new antibiotics1 with the potential to treat serious bacterial infections in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients.* This snapshot of the antibiotic pipeline will be updated periodically as products advance or are known to drop out of development. Please contact Rachel Zetts at [email protected] or 202-540-6557 with additions or updates. Cited for Potential Development Known QIDP4 Drug Name Company Drug Class Activity Against Gram- Potential Indication(s)5 Phase2 Designation? Negative Pathogens?3 New Drug Application Acute bacterial skin and skin structure Oritavancin The Medicines Company Glycopeptide Yes (NDA) submitted infections New Drug Application Acute bacterial skin and skin structure Dalbavancin Durata Therapeutics Lipoglycopeptide Yes (NDA) submitted infections NDA submitted (for Acute bacterial skin and skin structure acute bacterial skin infections, hospital acquired bacterial Tedizolid Cubist Pharmaceuticals Oxazolidinone Yes and skin structure pneumonia/ventilator acquired bacterial infection indication) pneumonia ACHN-975 Phase 1 Achaogen LpxC inhibitor Yes Bacterial infections Acute bacterial skin and skin structure infections6, methicillin-resistant Fabl inhibitor (AFN-1252 AFN-1720 Phase 1 Affinium Pharmaceuticals Staphylococcus aureus (MRSA) pulmonary pro-drug) infections
    [Show full text]
  • Antibiotic Update
    3/5/2015 Disclosure Antibiotic Update • I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this Ashley Gustafson, Pharm.D., BCPS continuing education activity, or any affiliation PGY-2 Critical Care Pharmacy Resident with an organization whose philosophy could potentially bias my presentation Baptist Hospital of Miami Pharmacist Objectives Technician Objectives • Review antimicrobial resistance patterns • Recognize new antimicrobial agents and their appropriate use in infectious disease • Assess new antimicrobial agents and their appropriate indications • Discuss what is new in the antimicrobial pipeline • Discuss what is new in the antimicrobial pipeline • Explain why antimicrobial stewardship is • Explain why antimicrobial stewardship is important important Antibiotic Resistance Threats Antibiotic Resistance Variable Microbes Humans Factor “The microbes are educated to resist penicillin ...… In such No. on earth 5 x 10 31 6 x 10 9 ~ 10 22 cases the thoughtless person playing with penicillin is morally responsible for the death of the man who finally succumbs to Mass, metric ton 5 x 10 16 3 x 10 8 ~ 10 8 infection with the penicillin-resistant organism. I hope this evil 5 can be averted.” Generation time 30 min 30 years ~ 5 x 10 - Sir Alexander Fleming 1945 Time on earth, 3.5 x 10 9 4 x 10 6 ~ 10 3 years Spellberg B et al. CID 2008;46:155-64 1 3/5/2015 Antibiotic Resistance Antibiotic Pressure • Existed before antibiotics • Caused by 4 general mechanisms –
    [Show full text]
  • Brilacidin Demonstrates Inhibition of SARS-Cov-2 in Cell Culture
    Article Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture Allison Bakovic 1, Kenneth Risner 1 , Nishank Bhalla 1, Farhang Alem 1 , Theresa L. Chang 2, Warren K. Weston 3, Jane A. Harness 3 and Aarthi Narayanan 1,* 1 National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA; [email protected] (A.B.); [email protected] (K.R.); [email protected] (N.B.); [email protected] (F.A.) 2 Public Health Research Institute, Rutgers, New Jersey Medical School, The State University of New Jersey, Newark, NJ 07103, USA; [email protected] 3 Innovation Pharmaceuticals Inc., Wakefield, MA 01880, USA; [email protected] (W.K.W.); [email protected] (J.A.H.) * Correspondence: [email protected]; Tel.: +1-703-993-9610 Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the newly emergent causative agent of coronavirus disease-19 (COVID-19), has resulted in more than two million deaths worldwide since it was first detected in 2019. There is a critical global need for therapeutic interven- tion strategies that can be deployed to safely treat COVID-19 disease and reduce associated morbidity and mortality. Increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs), also referred to as Host Defense Proteins/Peptides (HDPs), can inhibit SARS-CoV-2, paving the way for the potential clinical use of these molecules as therapeutic options. In this manuscript, we describe the potent antiviral activity exerted by brilacidin—a de novo designed synthetic small molecule that captures the biological properties of HDPs—on SARS-CoV-2 in a human lung cell line Citation: Bakovic, A.; Risner, K.; (Calu-3) and a monkey cell line (Vero).
    [Show full text]
  • Recent Advances in the Development of Antibacterial Agents
    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences Recent Advances in the Development of Antibacterial Agents. Avin S, A Avinash, Navin Patil, Sushil Kiran Kunder, Anurag Pathak, and KL Bairy*. Department of Pharmacology, Kasturba Medical College, Manipal, Karnataka, India. ABSTRACT Antibacterials are one of the most commonly prescribed groups of medications, especially in developing nations, owing to the vast number of microbial diseases prevalent in the community. Ever since the discovery of the phenomenal antibacterial, penicillin, there has been a great rise in the number of antibacterials in the market. In this era, where roadblocks like chemo-resistance and mutations plague medicine, scientists across the world are looking to adapt lateral approaches in encountering diseases. This review article brings to limelight, the recent advances in the field of antibacterial drug development, from the year 2007 till date. Keywords: Oritavancin, Tedizolid, Dalbavancin, Raxibacumab, Bedaquiline, Ceftaroline *Corresponding author September - October 2015 RJPBCS 6(5) Page No. 1220 ISSN: 0975-8585 INTRODUCTION Infectious diseases are among the leading causes of mortality worldwide, especially in developing nations where second line antibacterial drugs against resistant bacteria are generally either unavailable or unaffordable. The emergence of multi-drug resistance (MDR) in both community-acquired and hospital- acquired infections has outpaced the development and delivery of new drugs to the clinic. While the market potential for new antibacterial drugs is estimated to be several billions of dollars, the discovery pipelines of most major pharmaceutical companies are running near empty. The paucity of new antibacterial drugs has led the Infectious Disease Society of America (IDSA) and other bodies to call for action in rebuilding the infrastructure and efforts to develop next generation drugs [1].
    [Show full text]
  • Self-Assembling Dipeptide Antibacterial Nanostructures with Membrane Disrupting Activity
    ARTICLE DOI: 10.1038/s41467-017-01447-x OPEN Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity Lee Schnaider1, Sayanti Brahmachari1, Nathan W. Schmidt2, Bruk Mensa2, Shira Shaham-Niv1, Darya Bychenko1, Lihi Adler-Abramovich3, Linda J.W. Shimon 4,Sofiya Kolusheva5, William F. DeGrado 2 & Ehud Gazit1,6 Peptide-based supramolecular assemblies are a promising class of nanomaterials with important biomedical applications, specifically in drug delivery and tissue regeneration. 1234567890 However, the intrinsic antibacterial capabilities of these assemblies have been largely overlooked. The recent identification of common characteristics shared by antibacterial and self-assembling peptides provides a paradigm shift towards development of antibacterial agents. Here we present the antibacterial activity of self-assembled diphenylalanine, which emerges as the minimal model for antibacterial supramolecular polymers. The diphenylala- nine nano-assemblies completely inhibit bacterial growth, trigger upregulation of stress- response regulons, induce substantial disruption to bacterial morphology, and cause membrane permeation and depolarization. We demonstrate the specificity of these membrane interactions and the development of antibacterial materials by integration of the peptide assemblies into tissue scaffolds. This study provides important insights into the significance of the interplay between self-assembly and antimicrobial activity and establishes innovative design principles toward the development of antimicrobial agents and materials. 1 Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel. 2 Department of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94158, USA. 3 Department of Oral Biology, The Goldschleger School of Dental Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0243117 A1 MENON (43) Pub
    US 20160243117A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0243117 A1 MENON (43) Pub. Date: Aug. 25, 2016 (54) HOST DEFENSE PROTEIN (HDP) MIMETICS Publication Classification FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE (51) Int. Cl. GASTRONTESTINAL TRACT A613 L/506 (2006.01) A6II 45/06 (2006.01) (71) Applicant: CELLCEUTIX CORPORATION, A63/67 (2006.01) BEVERLY, MA (US) (52) U.S. Cl. CPC ............. A6 IK3I/506 (2013.01); A61 K3I/I67 (72) Inventor: Krishna MENON, Beverly, MA (US) (2013.01); A61K 45/06 (2013.01) (73) Assignee: CELLCEUTIX CORPORATION, BEVERLY, MA (US) (57) ABSTRACT (21) Appl. No.: 15/042.923 (22) Filed: Feb. 12, 2016 The present invention provides methods for treating and/or preventing inflammatory diseases of the gastrointestinal tract Related U.S. Application Data with one or more compounds, orpharmaceutically acceptable (60) Provisional application No. 62/118,950, filed on Feb. salts thereof, disclosed herein, and the use of compositions 20, 2015. comprising the same. Patent Application Publication Aug. 25, 2016 Sheet 1 of 15 US 2016/02431 17 A1 Figure : VX3.3 tilitic of EAB 3: .. 2. 5 10000 8.8 .. PVX30.063 Concentration iv) Patent Application Publication Aug. 25, 2016 Sheet 2 of 15 US 2016/02431 17 A1 Figare 2 PVX6S ribition of PE432 3: .. 25000 20000 15000 10000 5000 { . PVX6056 concestration iv Patent Application Publication Aug. 25, 2016 Sheet 3 of 15 US 2016/02431 17 A1 Figure 3 PVX363 inhibition of E3A 3 . 2 s: 10000 5000 PVX3063 concentration M Patent Application Publication Aug.
    [Show full text]
  • Recent Advances in Design of Antimicrobial Peptides and Polypeptides Toward Clinical Translation
    Advanced Drug Delivery Reviews 170 (2021) 261–280 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation Yunjiang Jiang a,b, Yingying Chen a, Ziyuan Song a, Zhengzhong Tan a, Jianjun Cheng a,b,c,d,⁎ a Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, 1304 W Green Street, Urbana, IL 61801, United States b Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, 405 N Mathews Ave, Urbana, IL 61801, United States c Department of Bioegineering, University of Illinois at Urbana-Champaign, 1406 W Green Street, Urbana, IL 61801, United States d Department of Chemistry, University of Illinois at Urbana-Champaign, 505 S Mathews Ave, Urbana, IL 61801, United States article info abstract Article history: The recent outbreaks of infectious diseases caused by multidrug-resistant pathogens have sounded a piercing Received 9 October 2020 alarm for the need of new effective antimicrobial agents to guard public health. Among different types of Received in revised form 16 December 2020 candidates, antimicrobial peptides (AMPs) and the synthetic mimics of AMPs (SMAMPs) have attracted signifi- Accepted 28 December 2020 cant enthusiasm in the past thirty years, due to their unique membrane-active antimicrobial mechanism and Available online 02 January 2021 broad-spectrum antimicrobial activity. The extensive research has brought many drug candidates into clinical and pre-clinical development. Despite tremendous progresses have been made, several major challenges inher- Keywords: Antibiotic resistance ent to current design strategies have slowed down the clinical translational development of AMPs and SMAMPs.
    [Show full text]
  • Antibiotic-Loaded Polymeric Microspheres for Passive Lung Targeting After Intravenous Administration
    ANTIBIOTIC-LOADED POLYMERIC MICROSPHERES FOR PASSIVE LUNG TARGETING AFTER INTRAVENOUS ADMINISTRATION by MONICA AGNOLETTI M.Sc., University of Parma, 2016 A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES (Pharmaceutical Sciences) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) July 2020 © Monica Agnoletti, 2020 UNIVERSITY OF COPENHAGEN FACULTY OF HEALTH AND MEDICAL SCIENCES PhD Thesis Monica Agnoletti Antibiotic-loaded polymeric microspheres for passive lung targeting after intravenous administration This thesis has been submitted to the Graduate School of Health and Medical Sciences, University of Copenhagen on March 15, 2020 The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, the dissertation entitled: Antibiotic-loaded polymeric microspheres for passive lung targeting after intravenous adminiatration submitted by Monica Agnoletti in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences Examining Committee: Susan Weng Larsen, Faculty of Health and Medical Sciences, University of Copenhagen University Examiner Marcel Bally, Faculty of Medicine, University of British Columbia University Examiner Simon Bjerregaard, Ferring Pharmaceuticals External Examiner Additional Supervisory Committee Members: - Supervisory Committee Member - Supervisory Committee Member i Academic Advisors Urs Otto Häfeli Professor,
    [Show full text]
  • Antimicrobial Lipopeptide Tridecaptin A1 Selectively Binds to Gram-Negative Lipid II
    Antimicrobial lipopeptide tridecaptin A1 selectively binds to Gram-negative lipid II Stephen A. Cochranea,1, Brandon Findlaya,1, Alireza Bakhtiarya, Jeella Z. Acedoa, Eva M. Rodriguez-Lopeza, Pascal Mercierb, and John C. Vederasa,2 aDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada T6G 2G2; and bNational High Field NMR Centre, University of Alberta, Edmonton, AB, Canada T6G 2E1 Edited by Samuel H. Gellman, University of Wisconsin, Madison, WI, and approved August 19, 2016 (received for review May 27, 2016) Tridecaptin A1 (TriA1) is a nonribosomal lipopeptide with selective Results antimicrobial activity against Gram-negative bacteria. Here we show Tridecaptin A1 Targets the Cell Membrane. Our initial efforts focused that TriA exerts its bactericidal effect by binding to the bacterial cell- 1 on identifying the mode of action of TriA1. Measuring the time wall precursor lipid II on the inner membrane, disrupting the proton taken for an antibiotic to exert its antimicrobial effect can provide motive force. Biochemical and biophysical assays show that binding valuable information on the cellular process targeted by that to the Gram-negative variant of lipid II is required for membrane compound. Bacteriostatic agents halt cell division but do not re- disruption and that only the proton gradient is dispersed. The NMR duce the number of viable cells, and antibiotics that target protein solution structure of TriA1 in dodecylphosphocholine micelles with synthesis and nucleic acid synthesis typically fall within this cate- lipid II has been determined, and molecular modeling was used to gory. Bactericidal agents reduce the population of viable bacterial provide a structural model of the TriA –lipid II complex.
    [Show full text]